New combo therapy aims to slow tough prostate cancer

NCT ID NCT04704505

First seen Feb 06, 2026 · Last updated May 08, 2026 · Updated 10 times

Summary

This study tests a new treatment for men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The treatment combines a hormone therapy (testosterone) with a radioactive drug (radium-223) to try to slow cancer growth. About 47 men will receive both drugs every 28 days for up to 6 cycles. The goal is to see if this combination can delay the cancer from getting worse.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Amber Michalik

    RECRUITING

    Baltimore, Maryland, 20707, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Moinhos de Vento Hospital

    NOT_YET_RECRUITING

    Porto Alegre, 90560-010, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.